Sangamo Biosciences Has Option to Acquire Gendaq in Stock Deal Worth $40M | GenomeWeb

NEW YORK, May 30 - Sangamo Biosciences said Wednesday it has obtained the option to acquire privately-held Gendaq in a stock-for-stock deal worth $39.7 million.

Sangamo, which is currently completing due diligence, has until July 14 to exercise its option to acquire Gendaq, a London-based developer of zinc finger DNA binding proteins for gene regulating gene expression. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.